Zu einer Liste hinzufügen
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
259.30 CHF | -0.27% |
|
-3.86% | +1.49% |
20.06. | Roche legt positive Daten für Krebsmittel-Kombination vor | AW |
20.06. | Roche präsentiert positive Phase-III-Studienergebnisse zu Lunsumio | DJ |
Hauptkonkurrenten
Zu einer Liste hinzufügen 0 ausgewählt | Umsatz (Y-1) | Nettogewinn (Y-1) | EBIT-Marge (Y-1) | ROE (Y-1) | ROA (Y-1) | Verschuldungsgrad (Y-1) | |
---|---|---|---|---|---|---|---|
66.76 Mrd. | 13.68% | 34.42% | 43.45% | 15.69% | 0.74x | ||
45.04 Mrd. | 23.51% | 31.78% | 84.84% | 14.84% | 1.88x | ||
88.82 Mrd. | 15.84% | 29.8% | 34.23% | 13.95% | 0.36x | ||
40.31 Mrd. | 34.78% | 44.19% | 80.78% | 25.88% | 0.52x | ||
56.33 Mrd. | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
50.32 Mrd. | 23.73% | 38.74% | 34.74% | 15.58% | 0.85x | ||
54.07 Mrd. | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
64.17 Mrd. | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
33.42 Mrd. | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
63.63 Mrd. | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
28.75 Mrd. | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
42.53 Mrd. | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
11.02 Mrd. | -4.86% | 6.31% | 0.65% | 0.49% | -6.77x | ||
48.3 Mrd. | -18.53% | 10.77% | 10.23% | -9.53% | 6.49x | ||
7.45 Mrd. | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
39.28 Mrd. | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
3.83 Mrd. | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
14.06 Mrd. | 12.84% | 22.26% | 8.8% | 4.22% | 2.82x | ||
28.19 Mrd. | 3.38% | 5.02% | 2.1% | 0.36% | 4.66x | ||
Durchschnitt | 41.38 Mrd. | 13.48% | 30.06% | 50.67% | 10.59% | 1.00x | |
Gewichteter Durchschnitt nach Marktkapitalisierung | 49.82 Mrd. | 16.72% | 33.25% | 71.62% | 13.37% | 1.14x |
- Börse
- Aktien
- 855167 Aktie
- Sektor Roche Holding AG
- Finanzielle Vergleiche
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen

MarketScreener is also available in this country: United States.
Switch edition
Bei der aktuellen länderspezifischen Edition bleiben